RealTime Dynamix™: Psoriasis Q2
is the first report in a three-part 2016 series focusing on current and anticipated future trends in the PsO market. Report content also includes a detailed look at dermatologists’ adoption of Taltz. Major inline brands covered include Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, and Taltz. PsO pipeline agents covered include brodalumab, guselkumab, tildrakizumab, and the recently approved biosimilar, Inflectra. Here we spotlight some key findings from this robust study.